People with hemophilia are hesitant to take the FDA-approved drugs for a variety of reasons, experts say. Pharma and biotech companies have taken notice.
On a quest to bring new a new hemophilia gene therapy to the clinic, one research team leapt over hurdle after hurdle to produce enough viral therapeutics to treat a large number of patients.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.